Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental myeloma drug trial halted early

NCT ID NCT03374085

Terminated Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • Local Institution - 001

    Athens, 11528, Greece

  • Local Institution - 101

    Nashville, Tennessee, 37203, United States

  • Local Institution - 102

    Atlanta, Georgia, 30322, United States

  • Local Institution - 103

    Duarte, California, 91010-300, United States

  • Local Institution - 104

    New York, New York, 10065, United States

  • Local Institution - 105

    Boston, Massachusetts, 02115, United States

  • Local Institution - 106

    Houston, Texas, 77030, United States

  • Local Institution - 108

    Spartanburg, South Carolina, 29303, United States

  • Local Institution - 109

    Seattle, Washington, 98104, United States

  • Local Institution - 111

    Buffalo, New York, 14263, United States

  • Local Institution - 112

    Charlottesville, Virginia, 22908, United States

  • Local Institution - 150

    Seoul, 135-710, South Korea

  • Local Institution - 151

    Seoul, 3080, South Korea

  • Local Institution - 152

    Seoul, 120-752, South Korea

  • Local Institution - 201

    Calgary, Alberta, T2N 4N2, Canada

  • Local Institution - 202

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 203

    Québec, Quebec, G1J 1Z4, Canada

  • Local Institution - 204

    London, Ontario, N6C 6B5, Canada

  • Local Institution - 205

    Ottawa, Ontario, K1H 8L6, Canada

  • Local Institution - 206

    Montreal, Quebec, H4A 3J1, Canada

  • Local Institution - 301

    Sutton, SM2 5PT, United Kingdom

  • Local Institution - 302

    Oxford, OX3 7LE, United Kingdom

  • Local Institution - 303

    London, NW1 2PG, United Kingdom

  • Local Institution - 304

    Plymouth, Devon, PL6 8DH, United Kingdom

  • Local Institution - 305

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Local Institution - 306

    Cardiff, CF14 4XW, United Kingdom

  • Local Institution - 401

    Pamplona, 31008, Spain

  • Local Institution - 402

    Salamanca, 37007, Spain

  • Local Institution - 403

    Badalona (Barcelona), 08916, Spain

  • Local Institution - 404

    Madrid, 28041, Spain

  • Local Institution - 405

    Valencia, 46026, Spain

  • Local Institution - 406

    Cáceres, 10003, Spain

  • Local Institution - 407

    Barcelona, 08025, Spain

  • Local Institution - 408

    Santander, 39008, Spain

  • Local Institution - 409

    Pozuelo de Alarcón, 28223, Spain

  • Local Institution - 501

    Copenhagen, 2100, Denmark

  • Local Institution - 502

    Odense, 5000, Denmark

  • Local Institution - 503

    Aarhus N, DK-8200, Denmark

  • Local Institution - 601

    Helsinki, 00029, Finland

  • Local Institution - 701

    Okayama, 701-1192, Japan

  • Local Institution - 702

    Kobe, 650-0047, Japan

  • Local Institution - 703

    Fukuoka, 810-8563, Japan

  • Local Institution - 704

    Kashiwa, 277-8577, Japan

  • Local Institution - 705

    Chuo-ku,chiba, 260-8677, Japan

  • Local Institution - 706

    Kyoto, 602-8566, Japan

  • Local Institution - 802

    Adelaide, South Australia, 5000, Australia

  • Local Institution - 803

    Melbourne, Victoria, 3004, Australia

  • Local Institution - 804

    Camperdown, New South Wales, 2050, Australia

  • Local Institution - 805

    Clayton, Victoria, 3168, Australia

  • Local Institution - 806

    Fitzroy, 3065, Australia

  • Local Institution - 901

    Leuven, 3000, Belgium

  • Local Institution - 902

    Yvoir, 5530, Belgium

  • Local Institution - 904

    Antwerp, 2060, Belgium

  • Local Institution - 905

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.